The Leicester Drug Discovery and Diagnostics (LD3) translates the University’s high quality biomedical research into medicines, therapies and diagnostic tests with ‘real world’ benefit for patients.

We work with industrial partners to deliver novel medicines and diagnostics with strong academic leadership and support from knowledge transfer professionals. The LD3 has dedicated staff and state-of-the-art laboratories and has received a number of MRC Confidence in Concept Awards.

We benefit from the expertise of clinical academics with access to patients and links to Clinical Trials Units, which support a wide range of trials from first in man through to complex efficacy studies.

Our portfolio includes infectious, respiratory, cardiovascular, and neuro-degenerative diseases and oncology alongside the development of new precision medicine approaches including novel diagnostics.

LD3’s partnerships include leading pharmaceutical companies, small biotechnology companies and contract research organisations, as well as the technology transfer branches of major charities such as LifeArc and Cancer Research Technology (CRT).

We seek to match the pharmaceutical and biotech industry’s needs with the outstanding expertise of our academics.

Our dedicated team of scientists enable us to:

Validate biological targets

Perform NMR and crystallography

Develop cell based assays

Provide project management in line with Good Clinical Practices (GCP), Human Tissues Act (HTA) and the Animals Scientific Procedures Act (ASPA) legislation

Work with ex-vivo and in-vivo pre-clinical models

Take projects towards “first in man” trials with colleagues from Leicester Clinical Trials Unit


Share this page:

Contact us

LD3 Research Manager, 

Dr. Christine Alberti-Segui:

+44 (0) 116 252 5174

LD3 Office:

+44 (0) 116 252 3342              


Contact Details

College of Life Sciences
University of Leicester
Maurice Shock Building
University Road